EMA recommends granting a marketing authorisation for relacorilant

Дата публикации: 02-10-2026 07:00:00

It is intended for the treatment of adult patients with epithelial ovarian, Fallopian tube or primary peritoneal cancer

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	EMA Recommends Granting a Marketing Authorisation for Ensartinib	0	13.61	09-10-2026
2	EMA recommends extension of indications for pirtobrutinib	0	8.86	25-09-2026
3	GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan	0	14.91	23-03-2026
4	Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS	0	8.71	30-09-2026
5	Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer	0	9.74	24-08-2026
6	FDA approves Welireg-Lenvima combination for advanced RCC	0	10.87	24-09-2026
7	FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer	0	14.79	23-09-2026
8	Clinical trial to treat rectal cancer spares major surgery	0	8.49	24-08-2026
9	Tambotatug pelitecan leads to better clinical outcomes than topotecan among patients with relapsed SCLC after platinum-based therapy	0	14.55	28-09-2026
10	MAIBE for Patients With Locally Advanced Pancreatic Cancer	0	5.92	01-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.25. Источник: www.esmo.org.